| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Cabazitaxel |
| Brand | Jevtana® |
| Indication | Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. |
| Assessment Process | |
| Rapid review commissioned | 02/06/2011 |
| Rapid review completed | 09/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended. |
| Full submission received from Applicant | 03/11/2011 |
| NCPE assessment completed | 13/03/2012 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price. |
The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.
The HSE has approved reimbursement following confidential price negotiations; March 2014.
